Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

February 9, 2021 Providence Cancer Institute of Oregon

Join Providence Cancer Institute and the Society for Immunotherapy of Cancer (SITC) on Thursday, April 8, 2021, for Advances in Cancer Immunotherapy™, a live free program featuring the latest clinical advancements in cancer immunotherapy and most recent FDA-approvals. This program is recommended for healthcare professionals in clinical settings, students, and patient advocates, and will feature leading authorities in tumor immunology and cancer immunotherapy from the Earle A. Chiles Research Institute, a division of Providence.

Highlights include:

• Interactive, virtual setting to connect with local faculty and organizers

• Learning how to treat patients with FDA-approved immunotherapies

• A deep dive into identifying and managing Immune-Related Adverse Events

• COVID-19 considerations from the speakers’ direct experience

• Interpreting new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines

Attendees will also have an opportunity to connect with regional experts in the immunotherapy field at the live event, through four quarterly webinars, and indefinitely through a dedicated online community forum. These connections will serve as ongoing resources while clinical oncologists and other healthcare providers incorporate immunotherapy into practice.

Event Details:
Date: Thursday, April 8, 2021
Time: 3:00pm – 8:00pm PST

Organizers:

Amy Hartman, DNP, FNP-C, Providence Cancer Institute

Rachel Sanborn, MD, Earle A. Chiles Research Institute at Providence Cancer Institute

Sasha Stanton, MD, PhD, Earle A. Chiles Research Institute at Providence Cancer Institute

Register for free

To learn more, or to view the full program, please click here.

Welcome to your journey for creating a healthier you

Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

Previous Article

Next Article

Register now for SITC Advances in Cancer Immunotherapy™ Live Virtual Program

Previous Article

Next Article

Other content in this Stream

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

The radiation oncology team at Joe Arrington Cancer Center is awarded APEx Accreditation for excellent care.

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

Patient Navigators provide a wealth of information and support to patients and families at all three Providence oncology locations: Lacey, Centralia and Aberdeen.